Pharmacoeconomics and Health Outcomes Driving Formulary Access and Reimbursement

With ever-increasing pressures from managed care organizations, government agencies, pharmacy benefit managers and other reimbursement groups for pharmaceutical companies to prove their products’ value, pharmacoeconomics is a becoming a more and more important science. Empowered and well-funded health outcomes groups can help pharma companies earn their way on to tough-to-crack formularies, justify premium pricing, and provide convincing data for sales forces influencing prescribers. These groups can also inform early research termination decisions, help judge partnership opportunities and much more.

Pharmacoeconomics and Health Outcomes: Driving Formulary Access and Reimbursement examines the inner workings of pharmacoeconomics and health outcomes functions. From structures and communication links to budget amounts and control to departmental staffing levels, the report details the strategies of some of the industry’s top pharmacoeconomics groups.

The information contained within this report is gathered from numerous global pharmacoeconomics and health outcomes directors, associate directors and leaders. From phase- by-phase brand-level pharmacoeconomics spending to resource allocation, this report guides health outcomes groups to greater success.

This report is divided into 9 chapters. The first 8 chapters profile each participating company’s pharmacoeconomics/health outcomes department. The last chapter provides comparisons across all of the examined groups.

Published 2007

163 Pages

250+ Metrics

100+ Charts and Diagrams
Table of Contents
Price: $7,695.00 / GBP3,847.50